Inclusion Complexation of Lorazepam with Different Cyclodextrins Suitable for Parenteral Use

Autor:	Yvan Vander Heyden, Jacqueline Plaizier-Vercammen, Chantal Holvoet
Rok vydání:	2005
Předmět:	medicine.drug_class Chemistry Pharmaceutical Pharmaceutical Science Lorazepam Inclusion compound Excipients Hypnotic chemistry.chemical_compound Drug Stability Drug Discovery medicine Animals Humans Solubility Maltose Chromatography High Pressure Liquid Drug Packaging Parenteral solutions Pharmacology chemistry.chemical_classification Cyclodextrins Chromatography Cyclodextrin beta-Cyclodextrins Organic Chemistry Reproducibility of Results Sterilization Hydrogen-Ion Concentration 2-Hydroxypropyl-beta-cyclodextrin Dilution chemistry Delayed-Action Preparations Sedative Isotonic Solutions Injections Intraperitoneal gamma-Cyclodextrins medicine.drug
Zdroj:	Drug Development and Industrial Pharmacy. 31:567-575
ISSN:	1520-5762 0363-9045
DOI:	10.1080/03639040500214738
Popis:	The development of a parenteral lorazepam formulation, using cyclodextrins (CDs) as inclusion complexation agents, was investigated. CDs suitable for parenteral injection, i.e., hydroxypropyl-beta-cyclodextrin (HP-beta-CD), hydroxypropyl-gamma-cyclodextrin (HP-gamma-CD), sulfobutylether-7-beta-cyclodextrin (SBE-7-beta-CD), and maltosyl-beta-cyclodextrin (malt-beta-CD) were studied for the possibility to increase the solubility of lorazepam. Lorazepam interacted with all tested CD derivatives and 1:1 complexes are formed. HP-beta-CD exerts the highest solubility improvement, reaching about 6 mg/ml lorazepam in 30% (w/v) CD solution. When using SBE-7-beta-CD or malt-beta-CD only half of that concentration can be dissolved. HP-gamma-CD interacts much less with lorazepam. Parenteral solutions with 4 mg/ml in 30% (w/v) HP-beta-CD solution, with 2 mg/ml in 30% (w/v) SBE-7-beta-CD, and with 2 mg/ml lorazepam in 15% (w/v) HP-beta-CD, were prepared. Sterile filtration of the formulation needs to be applied because of massive degradation of lorazepam during autoclaving. No precipitation is observed after dilution of the different formulations with (physiological) water or with 5% dextrose in water, which proves their suitability for administration with perfusions. The stability of the preparations was investigated in aqueous medium. During the first month, in all solutions more than 90% of lorazepam remained; after 3 months, less than 60% of lorazepam remained in the solutions with 15% (w/v) HP-beta-CD and around 65-70% in the solutions with 30% (w/v) of CDs. Because of this short stability time, the preparations need to be lyophilized.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f36c76817ae6f47e98e2b472aa14f3 https://doi.org/10.1080/03639040500214738 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.